Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-04-26

FDA Approved: BENLYSTA — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approves a supplemental application for Belimumab (Benlysta) submitted by GlaxoSmithKline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BENLYSTA (belimumab)

Snippet

SUPPL AP for BENLYSTA (BELIMUMAB)